AIP
KROS icon

Ameritas Investment Partners’s Keros Therapeutics KROS Stock Holding History

Ameritas Investment Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Hold
2,372
– – ﹤0.01% 2470
2025
Q4 		$48.3K Sell
2,372
-515
-18% -$9.04K ﹤0.01% 2146
2025
Q3 		$45.7K Hold
2,887
– – ﹤0.01% 2196
2025
Q2 		$38.5K Hold
2,887
– – ﹤0.01% 2351
2025
Q1 		$29.4K Hold
2,887
– – ﹤0.01% 2388
2024
Q4 		$45.7K Hold
2,887
– – ﹤0.01% 2238
2024
Q3 		$168K Hold
2,887
– – 0.01% 1438
2024
Q2 		$132K Buy
2,887
+327
+13% +$17.6K ﹤0.01% 1552
2024
Q1 		$169K Buy
2,560
+324
+14% +$19.2K 0.01% 1403
2023
Q4 		$88.9K Hold
2,236
– – ﹤0.01% 1818
2023
Q3 		$71.3K Buy
2,236
+377
+20% +$14.1K ﹤0.01% 1878
2023
Q2 		$74.7K Buy
1,859
+448
+32% +$19.6K ﹤0.01% 1789
2023
Q1 		$60.3K Hold
1,411
– – ﹤0.01% 1855
2022
Q4 		$72.5K Hold
1,411
– – ﹤0.01% 1815
2022
Q3 		$53K Buy
1,411
+319
+29% +$11.1K ﹤0.01% 1938
2022
Q2 		$30K Hold
1,092
– – ﹤0.01% 2316
2022
Q1 		$59K Hold
1,092
– – ﹤0.01% 1962
2021
Q4 		$64K Hold
1,092
– – ﹤0.01% 1981
2021
Q3 		$43K Hold
1,092
– – ﹤0.01% 2261
2021
Q2 		$46K Hold
1,092
– – ﹤0.01% 2244
2021
Q1 		$67K Hold
1,092
– – ﹤0.01% 1905
2020
Q4 		$77K Buy
1,092
+477
+78% +$30.1K ﹤0.01% 1716
2020
Q3 		$24K Hold
615
– – ﹤0.01% 2286
2020
Q2 		$23K Buy
+615
New +$18.9K ﹤0.01% 2292

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Ameritas Investment Partners's KROS Position: Q1 2026 in Review

Ameritas Investment Partners held its Keros Therapeutics (KROS) position steady in Q1 2026 at 2,372 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

Ameritas Investment Partners first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $169K in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Ameritas Investment Partners held 2,372 shares of Keros Therapeutics worth $26.2K as of Q1 2026.
  • Ameritas Investment Partners left its Keros Therapeutics share count unchanged in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2470 holding.
  • Ameritas Investment Partners first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Ameritas Investment Partners's Keros Therapeutics position peaked at $169K in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.